Literature DB >> 14698224

TIR domain-containing adaptors define the specificity of TLR signaling.

Masahiro Yamamoto1, Kiyoshi Takeda, Shizuo Akira.   

Abstract

The concept that Toll-like receptors (TLRs) recognize specific molecular patterns in various pathogens has been established. In signal transduction via TLRs, MyD88, which harbors a Toll/IL-1 receptor (TIR)-domain and a death domain, has been shown to link between TLRs and MyD88-dependent downstream events leading to proinflammatory cytokine production and splenocyte proliferation. However, recent studies using MyD88-deficient mice have revealed that some TLRs possess a MyD88-independent pathway, which is represented by interferon (IFN)-beta production induced by LPS stimulation. This indicates that additional signaling molecules other than MyD88 exist in the TLR signaling pathway. Indeed, two additional TIR domain-containing adaptors, TIRAP/Mal and TRIF, have recently been identified. Both define the specific biological responses of each TLR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14698224     DOI: 10.1016/j.molimm.2003.10.006

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  100 in total

Review 1.  Regulation of microglial activation in stroke.

Authors:  Shou-Cai Zhao; Ling-Song Ma; Zhao-Hu Chu; Heng Xu; Wen-Qian Wu; Fudong Liu
Journal:  Acta Pharmacol Sin       Date:  2017-03-06       Impact factor: 6.150

Review 2.  Cell type- and stimulus-specific mechanisms for post-transcriptional control of neutrophil chemokine gene expression.

Authors:  Thomas Hamilton; Xiaoxia Li; Michael Novotny; Paul G Pavicic; Shyamasree Datta; Chenyang Zhao; Justin Hartupee; Dongxu Sun
Journal:  J Leukoc Biol       Date:  2011-12-13       Impact factor: 4.962

Review 3.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

4.  A constitutive shade-avoidance mutant implicates TIR-NBS-LRR proteins in Arabidopsis photomorphogenic development.

Authors:  Ana Faigón-Soverna; Franklin G Harmon; Leonardo Storani; Elizabeth Karayekov; Roberto J Staneloni; Walter Gassmann; Paloma Más; Jorge J Casal; Steve A Kay; Marcelo J Yanovsky
Journal:  Plant Cell       Date:  2006-11-17       Impact factor: 11.277

Review 5.  New players in TLR-mediated innate immunity: PI3K and small Rho GTPases.

Authors:  Monica Ruse; Ulla G Knaus
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

6.  MyD88 innate immune function in a zebrafish embryo infection model.

Authors:  Astrid M van der Sar; Oliver W Stockhammer; Carina van der Laan; Herman P Spaink; Wilbert Bitter; Annemarie H Meijer
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

7.  Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway.

Authors:  Guoying Zhang; Jingyan Han; Emily J Welch; Richard D Ye; Tatyana A Voyno-Yasenetskaya; Asrar B Malik; Xiaoping Du; Zhenyu Li
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

Review 8.  Targeting of immune signalling networks by bacterial pathogens.

Authors:  Igor E Brodsky; Ruslan Medzhitov
Journal:  Nat Cell Biol       Date:  2009-05       Impact factor: 28.824

9.  Genetic analysis of Toll/Interleukin-1 Receptor (TIR) domain sequences from rhesus macaque Toll-like receptors (TLRs) 1-10 reveals high homology to human TLR/TIR sequences.

Authors:  Sonali K Sanghavi; Raj Shankarappa; Todd A Reinhart
Journal:  Immunogenetics       Date:  2004-11-11       Impact factor: 2.846

10.  Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and -independent mechanisms.

Authors:  Maryam Ahmed; Latoya M Mitchell; Shelby Puckett; Kristina L Brzoza-Lewis; Douglas S Lyles; Elizabeth M Hiltbold
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.